Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke

Phase 3

Recruiting

• Conditions: Stroke, Ischemic; Stroke, Acute
• Interventions: Drug: Placebo; Drug: Tenecteplase

• Registration Number: NCT05199194
• Lead Sponsor: Hospital Moinhos de Vento

Brief Summary

A phase III randomized, multi-center, double-blinded, placebo-controlled clinical trial that will examine two strategies for the treatment of acute ischemic stroke associated with a large vessel anterior occlusion within 4.5 hours from symptoms onset: direct endovascular treatment vs. endovascular treatment preceded by intravenous tenecteplase.

Detailed Description

Randomized, prospective, multicenter, double-blinded, placebo-controlled clinical trial with adaptive desing. Randomization will be 1:1 according to reperfusion treatment modalities: (A) (with placebo TNK) direct mechanical thrombectomy vs. (B) Intravenous thrombolysis with TNK (0.25 mg/kg) plus mechanical thrombectomy. Randomization will be done by a minimization process using age, National Institute of Health Stroke Scale (NIHSS) score, and site of the occluded artery. For the primary outcome, the subjects will be followed up within 90 days after randomization. The primary outcome will be the ordinal distribution from the modified Rankin scale score (mRS).

Subjects presenting acute ischemic stroke within 4.5 hours of the onset of symptoms attributable to an occlusion of intracranial internal carotid or of the proximal middle cerebral artery (MCA, M1- or M2-segment) with or without tandem occlusion of cervical internal carotid confirmed by vascular neuroimaging. Subjects should be eligible for IV thrombolysis. In the sample size calculation, a difference in treatment effect between the groups (achievement of mRS 0 to 2 at 90 days) of 10.6% was considered, with 33.8% in the intervention group (TNK + thrombectomy) and 23.2% in the control group (placebo + thrombectomy), using a unilateral alpha of 0.025, with a power of 80%, resulting in a sample size of 358 participants. Considering a loss ratio of 10%, a sample size of 398 participants is estimated (199 in each treatment arm). An interim analysis is planned to be executed with 50% and 75% of the total sample. It allows the trial to be terminated in the case of efficacy or futility, in addition to enabling adaptive designed based on conditional probability of a positive result.

Study Timeline

• Study First Submitted: 2022-01-06
• Study First Submitted QC: 2022-01-06
• Study First Posted: 2022-01-20
• Study Start: 2022-05-27
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-02
• Last Update Posted: 2025-04-04
• Primary Completion: 2026-07
• Study Completion: 2027-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 398

Inclusion Criteria

• Acute ischemic stroke where a patient is eligible for IV thrombolytic treatment within 4.5 hours of stroke onset.

• No significant pre-stroke functional disability (mRS ≤ 1)

• Baseline NIHSS scores obtained before randomization must be equal to or higher than 6 points

• Age equal ≥ 18 and =< 85 years

• Occlusion (TICI 0-1) of the ICA or proximal MCA segments (M1 or M2) suitable for endovascular treatment, as evidenced by CTA, MRA, or angiogram, with or without concomitant cervical carotid stenosis or occlusion.

• Patient randomized within 4.5 hours of symptom onset. Symptoms onset is defined as the point in time the patient was last seen well (at baseline). Treatment start is defined as groin puncture, max 90 minutes after randomization.

  • Patients who have woken up with the symptoms and who have a mismatch FLAIR-DWI according to the WAKE-UP Trial will be considered as having a time window of <4.5h.

• Informed consent obtained from the patient or acceptable patient surrogate.

Exclusion Criteria

• Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 1.7 or direct oral anticoagulants such as thrombin antagonists (ex: dabigatran) or X factor (ex: rivaroxaban, apixaban, edoxaban) at the least 48 hours.
• Baseline platelet count < 100.000/μL
• Baseline blood glucose of < 50mg/dL or > 400mg/dl
• Severe, sustained hypertension (SBP > 185 mm Hg or DBP > 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA guidelines recommended medication (including iv antihypertensive drips), the patient can be enrolled.
• Patients in coma (NIHSS item of consciousness >1) (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation).
• Seizures at stroke onset which would preclude obtaining a baseline NIHSS
• Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.
• History of life-threatening allergy (more than rash) to contrast medium.
• Subjects who has received IV t-PA treatment before the randomization.
• Renal failure with serum creatinine ≥ 3 mg/dl
• Woman of childbearing potential who is known to be pregnant or who has a positive pregnancy test on admission.
• Subject participating in a study involving an investigational drug or device that would impact this study.
• Cerebral vasculitis, endocarditis or subarachnoid hemorrhage.
• Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.
• Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas).
• Hypodensity on CT more than one third of MCA territory or hypersignal in more than one third of MCA territory on MR-DWI.
• ASPECTS score < 6 (no contrast at least 5 mm cut imaging on CT) or on MR-DWI sequence.
• CT or MR evidence of hemorrhage (the presence of < 5 GRE, SWI, SWAN microbleeds is allowed).
• Significant mass effect with midline shift.
• Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery/deployment.
• Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).
• Evidence of intracranial tumor (except small meningioma).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Mechanical Thrombectomy preceded by Placebo	Placebo	Subjects assigned to this arm will receive an intravenous bolus of matching placebo (with the same volume of infusion as of 0.25mg/kg of tenecteplase) before the mechanical thrombectomy.
Mechanical Thrombectomy preceded by TNK	Tenecteplase	Subjects assigned to this arm will receive an intravenous bolus of tenecteplase (0.25mg/kg) before the mechanical thrombectomy.

Primary Outcome Measures

Name	Time	Method
Distribution of the modified Rankin Scale scores at 90 days	90 days	Distribution of the modified Rankin Scale scores (shift analysis).

Secondary Outcome Measures

Name	Time	Method
Functional independence defined as modified Rankin Score ≤ 2	90 days	Functional independence defined as modified Rankin Score ≤ 2
Infarct volume evaluated on CT at 24 hours (-2/+12 hours).	24 hours	Infarct volume evaluated on CT at 24 hours (-2/+12 hours).
Dramatic early favorable response as determined by a National Institute of Health Stroke Scale (NIHSS) of 0-2 or NIHSS improvement ≥ 10 points at 24 (-2/+12 hours) hours.	24 hours	Dramatic early favorable response as determined by a National Institute of Health Stroke Scale of 0-2 or NIHSS improvement ≥ 10 points at 24 (-2/+12 hours) hours.
Cost-effectiveness analysis of endovascular therapy alone vs. endovascular therapy associated with tenecteplase	12 months	Cost-effectiveness analysis of endovascular therapy alone vs. endovascular therapy associated with tenecteplase
Quality of life analysis as measured by EuroQol/EQ5D at 3 month, 6 months and one year among the groups	3 months, 6 months and 12 months	Quality of life analysis as measured by EuroQol/EQ5D at 3 month, 6 months and one year among the groups
Score distribution of mRS at 90 days (shift analysis) in patients presenting M2-CMA occlusion	90 days	Score distribution of mRS at 90 days (shift analysis) in patients presenting M2-CMA occlusion
Vessel recanalization evaluated by CT angiography or MRA at 24 hours in both treatment groups	24 hours	Vessel recanalization evaluated by CT angiography or MRA at 24 hours in both treatment groups
Vessel recanalization post procedure in the endovascular arm assessed by TIMI grades and adjudicated by a central core-lab. Successful recanalization is defined as TICI (Thrombolysis in Cerebral Infarction) 2b or 3 on the post-procedure angiogram.	Immediately Post-procedure	Vessel recanalization post procedure in the endovascular arm assessed by TIMI grades and adjudicated by a central core-lab. Successful recanalization is defined as TICI (Thrombolysis in Cerebral Infarction) 2b or 3 on the post-procedure angiogram.

Trial Locations

Locations (13)

Hospital das Clínicas Botucatu; 🇧🇷 Botucatu, Brazil

Hospital das Clínicas da UFPR; 🇧🇷 Curitiba, Brazil

Hospital Sao Paulo; 🇧🇷 São Paulo, Brazil

Santa Casa de Misericordia de Sao Paulo; 🇧🇷 São Paulo, Brazil

Hospital Moinhos de Vento; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

Hospital de Base do Distrito Federal; 🇧🇷 Brasília, Brazil

Hospital de Base de Rio Preto; 🇧🇷 São José Do Rio Preto, Brazil

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto; 🇧🇷 Ribeirão Preto, Brazil

Hospital Geral de Fortaleza; 🇧🇷 Fortaleza, Brazil

Hospital das Clínicas de São Paulo; 🇧🇷 São Paulo, Brazil

Hospital Universitário de Uberlândia; 🇧🇷 Uberlândia, Brazil

Hospital Estadual Central; 🇧🇷 Vitória, Brazil

Hospital de Clinicas de Porto Alegre; 🇧🇷 Porto Alegre, Brazil